- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00064402
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
21 februari 2012 uppdaterad av: Sunovion
A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
Studieöversikt
Status
Avslutad
Betingelser
Detaljerad beskrivning
This was a double-blind, double-dummy, randomized, placebo- and active-controlled, multicenter, parallel-group study of adult subjects with COPD.
The study was double blinded through the use of both unit dose vial (UDV) and metered-dose inhaler (MDI) placebos, as appropriate.
The primary efficacy analysis utilized the placebo control.
Secondary analyses of the primary efficacy endpoint utilized the active control, and included comparisons between the placebo and active control.
This study was previously posted by Sepracor Inc.
In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Studietyp
Interventionell
Inskrivning (Faktisk)
741
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Alabama
-
Jasper, Alabama, Förenta staterna, 35501
- Pulmonary & Sleep Associates of Jasper, PC
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85006
- Pulmonary Associates, PA
-
Tucson, Arizona, Förenta staterna, 85712
- Arizona Clinical Research Center, Inc.
-
-
California
-
Fair Oaks, California, Förenta staterna, 95628
- Northern California Research Corp.
-
Fresno, California, Förenta staterna, 93720
- SARC Research Center
-
Fullerton, California, Förenta staterna, 92835
- California Research Medical Group, Inc.
-
Irvine, California, Förenta staterna, 92618
- Radiant Research-Irvine
-
Newport Beach, California, Förenta staterna
- West Coast Clinical Trials
-
Paramount, California, Förenta staterna, 90723
- Center for Clinical Trials, LLC
-
Rancho Mirage, California, Förenta staterna, 92270
- Advances in Medicine
-
San Diego, California, Förenta staterna, 92120
- Institute of HealthCare Assessment, Inc.
-
San Jose, California, Förenta staterna
- San Jose Clinical Research
-
Walnut Creek, California, Förenta staterna, 94598
- Allergy & Asthma Medical Group of Diablo Valley, Inc.
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80218
- Colorado Pulmonary Associates
-
Fort Collins, Colorado, Förenta staterna
- Northern Colorado Pulmonary Consultants, PC
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06106
- Physicians Research Center, Inc.
-
-
District of Columbia
-
Washington, District of Columbia, Förenta staterna
- Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, Förenta staterna, 33765
- Clinical Research of West Florida, Inc.
-
DeLand, Florida, Förenta staterna, 32720
- University Clinical Research, DeLand
-
Miami Beach, Florida, Förenta staterna, 33140
- Mt. Sinai Medical Center
-
Tampa, Florida, Förenta staterna, 33617
- Clinical Pharmacology Services
-
-
Georgia
-
Austell, Georgia, Förenta staterna, 30106
- Protocare Trial, Inc.
-
Marietta, Georgia, Förenta staterna, 30060
- Marietta Pulmonary Medicine
-
-
Illinois
-
O'Fallon, Illinois, Förenta staterna, 62269
- Office of Bradley Sakran, MD, PC
-
-
Indiana
-
South Bend, Indiana, Förenta staterna, 46617
- South Bend Clinic
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40215
- Family Allergy & Asthma Research Institute
-
Somerset, Kentucky, Förenta staterna
- Cumberland Lung and Sleep Specialists
-
-
Louisiana
-
Lafayette, Louisiana, Förenta staterna, 70503
- Bendel Medical Associates/Research
-
New Orleans, Louisiana, Förenta staterna
- New Orleans Center for Clinical Research
-
New Orleans, Louisiana, Förenta staterna, 70119
- New Orleans Center for Clinical Research
-
New Orleans, Louisiana, Förenta staterna, 70115
- Best Clinical Trials, LLC
-
Slidell, Louisiana, Förenta staterna, 70461
- North Shore Research Associates
-
Sunset, Louisiana, Förenta staterna, 70584
- Sunset Medical Research
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna
- University of Maryland-Airways Research Center
-
Wheaton, Maryland, Förenta staterna
- Institute of Asthma and Allergy
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02135
- Pro-Medica Clinical Research Center
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48106
- ClinSite, Inc.
-
-
Missouri
-
Saint Louis, Missouri, Förenta staterna, 63108
- Medex Healthcare Research, Inc.
-
St. Charles, Missouri, Förenta staterna, 63301-2847
- Midwest Chest Consultants, PC
-
St. Louis,, Missouri, Förenta staterna, 63122
- C.A.R.E Clinical Research
-
-
Montana
-
Butte, Montana, Förenta staterna
- Office of Keith Popovich, MD
-
Missoula, Montana, Förenta staterna
- Montana Medical Research, LLC
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna
- VA Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89119
- Advanced Biomedical Research of America
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Pulmonary Medicine
-
Charlotte, North Carolina, Förenta staterna, 28207
- Charlotte Lung and Health Center
-
Statesville, North Carolina, Förenta staterna, 28625
- Carolina Pharmaceutical Research, Inc.
-
Wilmington, North Carolina, Förenta staterna, 28412
- New Hanover Medical Research
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45241
- New Horizons Clinical Research, Inc.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73103
- COR Clinical Research LLC
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97213
- Allergy Associates Research Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Förenta staterna, 18104
- Northeast Clinical Research Centers, Inc.
-
Altoona, Pennsylvania, Förenta staterna, 16602
- Keystone Clinical Solutions
-
Philadelphia, Pennsylvania, Förenta staterna, 19146
- Philadelphia Health Associates - Adult Medicine
-
Ridley Park, Pennsylvania, Förenta staterna, 19078
- Consortium Clinical Research, Ltd.
-
-
Rhode Island
-
East Providence, Rhode Island, Förenta staterna, 02914
- Safe Harbor Clinical Research
-
-
South Carolina
-
Spartanburg, South Carolina, Förenta staterna, 29307
- Spartanburg Pharmaceutical Research
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37920
- Volunteer Research Group
-
-
Texas
-
Houston, Texas, Förenta staterna, 77084
- Breath of Life Research Institute
-
New Braunfels, Texas, Förenta staterna, 78130
- Central Texas Health Research
-
San Antonio, Texas, Förenta staterna, 78229
- Sylvana Research Associates
-
-
Virginia
-
Fredericksburg, Virginia, Förenta staterna, 22401
- Pulmonary Associates of Fredericksburg, Inc.
-
Richmond, Virginia, Förenta staterna, 23225
- Pulmonary Associates of Richmond, Inc.
-
-
Washington
-
Bellingham, Washington, Förenta staterna, 98225
- Bellingham Asthma, Allergy & Immunology Clinic
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- University of Wisconsin-Medical School
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
35 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Be willing to comply with study procedures and visit schedule
- Are at least 35 years of age
- Female subjects >65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization
- Subjects of childbearing potential must be using an acceptable method of birth control. Female subjects who are considered not of childbearing potential must be: documented surgically sterile, OR postmenopausal.
- Have a primary diagnosis of COPD. Diagnosis can be made during the screening process.
- Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).
- Have a chest x-ray that is consistent with the diagnosis of COPD and taken <3 months prior to study start
- Able to complete all study questionnaires and logs reliably
Exclusion Criteria:
- Female subject who is pregnant or lactating
- Have participated in an investigational drug study within 30 days prior to study start, or who is currently participating in another investigational drug study
- Subject whose schedule or travel prevents the completion of all required visits
- Are scheduled for in-patient hospitalization, including elective surgery during the trial
- Have life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days
- History of asthma or any chronic respiratory disease other than COPD (chronic bronchitis and/or emphysema)
- Have clinically significant cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
- Have a history of cancer except non-melanomatous skin cancer
- Have a history of lung resection of more than one full lobe
- Requires continuous supplemental oxygen therapy.
- Has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit
- Have a known sensitivity to arformoterol, ipratropium, salmeterol or albuterol or any of the excipients contained in any of these formulations
- Have a history of substance abuse or drug abuse within 12 months, or with a positive urine drug screen
- Are using any prescription drug for which concomitant beta-agonist administration is contraindicated (e.g., beta-blockers)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 1
Arformoterol 50 mcg QD and placebo MDI
|
arformoterol 50 mcg QD
Andra namn:
arformoterol 25 mcg BID
Andra namn:
arformoterol 15 mcg BID
Andra namn:
|
|
Experimentell: 2
Arformoterol 25 mcg BID and Placebo MDI
|
arformoterol 50 mcg QD
Andra namn:
arformoterol 25 mcg BID
Andra namn:
arformoterol 15 mcg BID
Andra namn:
|
|
Experimentell: 3
Arformoterol 15 mcg BID and placebo MDI
|
arformoterol 50 mcg QD
Andra namn:
arformoterol 25 mcg BID
Andra namn:
arformoterol 15 mcg BID
Andra namn:
|
|
Aktiv komparator: 4
Salmeterol MDI 42 mcg BID and placebo inhalation solution
|
Salmeterol MDI 42 mcg BID
Andra namn:
|
|
Placebo-jämförare: 5
Placebo MDI and placebo inhalation solution
|
Placebo BID
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period.
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Toppprocent av förutspådd FEV1
Tidsram: Vecka -2, 0, 3, 6, 9, 12
|
Vecka -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change from visit predose curve for FEV1 over 12 hours (nAUC0-12-P)
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change in FEV1 from study baseline over 12 hours (nAUC0-12-B)
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change from visit predose curve for FEV1 over 24 hours (nAUC0-24-P)
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time-normalized area under the percent change in FEV1 from study baseline curve over 24 hours (nAUC0-24-B)
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
peak percent change in FEV1 from visit predose and study baseline
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time point changes in FEV1; time to onset of response
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
time to peak change in FEV1
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
at-home and in-clinic peak expiratory flow rate (PEFR)
Tidsram: Weeks -2, 0, 3, 6, 9, 12
|
Weeks -2, 0, 3, 6, 9, 12
|
|
relationship between the plasma concentration values and selected pharmacodynamic parameters
Tidsram: Weeks -2, 0, 3, 6, 9, 12, 13
|
Weeks -2, 0, 3, 6, 9, 12, 13
|
|
Supplemental ipratropium bromide MDI and racemic albuterol MDI use
Tidsram: Weeks 0-13
|
Weeks 0-13
|
|
COPD exacerbations and COPD symptom ratings
Tidsram: Weeks 0-13
|
Weeks 0-13
|
|
St. George's Hospital Respiratory Questionnaire
Tidsram: Weeks 0, 6, 13
|
Weeks 0, 6, 13
|
|
Investigator and Subject Global Evaluations
Tidsram: Weeks -2, 12, 13
|
Weeks -2, 12, 13
|
|
Baseline and Transitional Dyspnea Index
Tidsram: Weeks -2, 6, 12
|
Weeks -2, 6, 12
|
|
distance walked in six minutes
Tidsram: Weeks -2, 3, 9
|
Weeks -2, 3, 9
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 april 2002
Primärt slutförande (Faktisk)
1 mars 2004
Avslutad studie (Faktisk)
1 mars 2004
Studieregistreringsdatum
Först inskickad
8 juli 2003
Först inskickad som uppfyllde QC-kriterierna
8 juli 2003
Första postat (Uppskatta)
9 juli 2003
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
22 februari 2012
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
21 februari 2012
Senast verifierad
1 februari 2012
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Infektioner
- Luftvägsinfektioner
- Luftvägssjukdomar
- Bronkialsjukdomar
- Lungsjukdomar
- Lungsjukdomar, obstruktiv
- Lungsjukdom, kronisk obstruktiv
- Emfysem
- Bronkit
- Bronkit, kronisk
- Läkemedels fysiologiska effekter
- Adrenerga medel
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Adrenerga agonister
- Bronkdilaterande medel
- Anti-astmatiska medel
- Andningsorgan
- Adrenerga beta-2-receptoragonister
- Adrenerga beta-agonister
- Farmaceutiska lösningar
- Salmeterol Xinafoate
- Formoterolfumarat
Andra studie-ID-nummer
- 091-051
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .